FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Sacrosidase (Sucraid) Oral Solution
Status: Currently in Shortage
»Date first posted: 07/09/2015
»Therapeutic Categories: Gastroenterology; Inborn Errors

QOL Medical, LLC (Revised 05/04/2017)

Company Contact Information:
772-584-3640

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
8,500 I.U./mL 118 mL per bottle, 2 bottles/box (NDC 67871-111-04) Limited availability from lot C1102 (approx. 670 boxes)? Shortage related to unavailable approved active pharmaceutical ingredient (API) from a supplier due to requirements related to complying with good manufacturing practices. There is a shortage of Sucraid because the process that has been used for making Sucraid does not meet FDA’s pharmaceutical standards, and the conversion to the required updated process has been delayed. Limited releases by QOL to date under informed consent due to ongoing shortage of approved product: Lot A1147 (expiration dates: 10/2015 and 05/2016), Lot A1150 (expiration date: 06/2017), Lot B1210 (expiration date: 07/2018*), Lot B1102 (expiration date: 06/2018), and Lot B1213 (expiration date: 07/2018), Lot C0502 (expiration date: 12/2018), Lot C0902 (expiration date: 04/2019), Lot C1201 (expiration date: 06/2019), Lot C1102 (expiration date: 05/2019).

Sucraid Lot C1102 Physician and Patient Informed Consent Forms to Obtain Product


Link to FDA Related Information for Sacrosidase Oral Solution
*Important Update: Expiration Date for Sucraid Lot B1210
Requirements related to complying with good manufacturing practices.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English